-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Izotropic Announces 2021 AGM Results
Izotropic Announces 2021 AGM Results
VANCOUVER, BC - TheNewswire - October 26, 2021 - Izotropic Corporation ("Izotropic" or the "Company") (CNSX:IZO.CN) (OTC:IZOZF) (FSE:1R3), a Company commercializing a dedicated breast CT (computed tomography) imaging platform, IzoView, for the more accurate detection and diagnosis of breast cancers is pleased to announce the results of its Annual General Meeting held via teleconference on October 2, 2021.
Company matters submitted to shareholders for approval as set out in the Company's Notice of Meeting and Management Information Circular, both dated September 8, 2021, were approved by a vote of 29.52% of issued and outstanding shares, the requisite majority of votes cast at the meeting.
The approvals included the following:
Election of Directors:
John McGraw
Robert Thast
John Boone
Ali Sodagar
Ralph Proceviat
Appointment of Auditor:
Dale Matheson Carr-Hilton LaBonte LLP
The Company wishes to thank Mr. Marshall Severyn for his contributions to Izotropic and his service to the company as a Director and Vice President of Marketing. Dr. John McGraw, the Company's current Chief Executive Officer, has been elected to the Board of Directors.
ON BEHALF OF THE BOARD
Dr. John McGraw, CEO
For investor relations inquiries, contact:
James Berard
Email: jberard@izocorp.com
Cell: 778-228-2314
Toll Free: 1-833-IZOCORP ext.1
About Izotropic Corporation
Izotropic Corporation is the only publicly traded company commercializing a dedicated breast CT imaging platform, IzoView, for the more accurate detection and diagnosis of breast cancers. To expedite patient and provider access to IzoView, Izotropic's initial clinical study intends to demonstrate superior performance of diagnostic breast CT imaging over diagnostic mammography procedures and will initiate in Q2 2022. In follow-on clinical studies, Izotropic intends to validate platform applications including breast screening in radiology, treatment planning and monitoring in surgical oncology, and breast reconstruction and implant monitoring in plastic and reconstructive surgery.
More information about Izotropic Corporation can be found on its website at izocorp.com and by reviewing its profile on SEDAR at sedar.com
Forward-Looking Statements
This document may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions, projections and expectations of the Company's management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words. These statements are not guarantees of performance and involve risks and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company's activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants, shall be liable for any action and the results of any action taken by any person based on the information contained herein, including without limitation the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind.
Copyright (c) 2021 TheNewswire - All rights reserved.
温哥华,公元前-新闻通讯社-10月26日, 2021 - 各向同性公司("各向同性“或”公司") (CNSX:以藏。氯化萘)(场外交易:IZOZF)(FSE:1R3), 一家公司为了更准确地检测和诊断乳腺癌,正在商业化的专用乳腺CT(计算机断层扫描)成像平台IzoView高兴地宣布,该公司于2021年10月2日通过电话会议召开的年度大会的结果。
日期均为2021年9月8日的本公司会议通知及管理资料通函所载呈交股东审批的公司事项,均以29.52%的已发行及已发行股份投票通过,此为大会所投的必要多数票。
这些批准包括以下内容:
董事选举:
约翰·麦格劳
罗伯特·萨克斯,约翰·布恩,阿里巴巴-SW,索达加尔,拉尔夫·普罗切瓦特
核数师的委任:
戴尔·马西森·卡尔-希尔顿·拉邦特律师事务所
公司感谢马歇尔·塞恩先生作为董事和营销副总裁为公司做出的贡献和为公司提供的服务。该公司现任首席执行官约翰·麦格劳博士已当选为董事会成员。
我代表BOARDDR。约翰·麦格劳(John McGraw),首席执行官
有关投资者关系的查询,请联系:
电子邮件:jberard@izocorp.com
电话:778-228-2314
免费电话:1-833-IZOCORP分机1
关于Izotroal公司
Izotroy公司是唯一一家将专用乳腺CT成像平台IzoView商业化的上市公司,该平台用于更准确地检测和诊断乳腺癌。为了加快患者和供应商使用IzoView的速度,Izotroy的初步临床研究打算证明诊断性乳房CT成像的性能优于诊断性乳房X光检查程序,并将于2022年第二季度启动。以下为-在临床研究方面,Izotroy公司打算验证平台应用,包括放射学中的乳房筛查、外科肿瘤学中的治疗计划和监测,以及整形和重建外科中的乳房重建和植入物监测。
欲了解有关Izotroy公司的更多信息,请访问该公司的网站:izocorp.com。并通过在SEDAR上查看其个人资料Sedar.com
前瞻性陈述
本文件可能包含“前瞻性陈述”,这些陈述基于对公司管理层、业务的当前估计、假设、预测和预期,以及对公司运营所处的相关市场和经济环境的了解。在可能的情况下,公司已尝试通过使用诸如“预期”、“相信”、“设想”、“估计”、“预期”、“打算”、“可能”、“计划”、“预测”、“计划”、“预测”、“项目”、“目标”、“潜在”、“将会”、“将会”、“可能”、“应该”、“继续”等词语来识别此类信息和陈述。关于未来事件、趋势或前景或未来经营或财务表现的任何讨论,“设想”及其他类似表述及其派生,尽管并非所有前瞻性表述都包含这些识别词汇。这些陈述不是对业绩的保证,涉及难以控制或预测的风险和不确定因素,因此,它们可能导致公司未来活动的结果与此类陈述的内容和影响大不相同。前瞻性陈述仅在作出之日起具有相关性,除非法律另有要求,否则公司没有义务更新或修改任何前瞻性陈述,以反映新信息或未来事件或情况的发生。本公司及其股东、高级管理人员和顾问均不对任何人根据本文包含的信息采取的任何行动以及任何行动的结果负责,包括但不限于购买或出售公司证券。本文档中的任何内容都不应被视为任何类型的医疗或其他建议。
版权所有(C)2021 TheNewswire-保留所有权利。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧